[PDF] Top 20 RESTAURACIÓN DE DIENTES ANTERIORES EN ODONTOPEDIATRÍA.pdf

... Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of morbidity and mortality worldwide, occurring in approximately one in 1000 adults ... See full document

... Abstract: Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients with ...decade, direct oral anticoagulants (DOACs) have recently emerged as a new ... See full document

... as venous thromboembolism ...the direct oral anticoagulants (DOAC; dabigatran, rivaroxaban, apixaban, edoxaban) in clinical trials testing these new compounds in the acute/ long-term ... See full document

... versus LMWH-VKA. This raises the question of whether variables are comparable when assessed on different scales. Quality of life after at least 3 months’ treatment was assessed on the EQ-5D questionnaire and on a verbal ... See full document

... evaluated direct oral anti- coagulants in patients with symptomatic DVT and/or PE used ...the direct Factor Xa inhibitor rivaroxaban, it was calculated that a total of 88 events were needed for each ... See full document

... Abstract: Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of ... See full document

... DOACs: Direct oral anticoagulants; VKAs: Vitamin K antagonists; VTE: Venous thromboembolism; NVAF: Non-valvular atrial fibrillation; CrCl: Creatinine clearance; AF: Atrial fibrillation; ... See full document

... for direct oral anticoagulants (DOACs), including factor X inhibi- tors and direct thrombin inhibitors, are a major concern in clinical ...of venous thromboembolism and ... See full document

... major bleeding events between the warfarin and dabiga- tran treatment arms, although minor bleeding events occurred significantly less frequently with dabigatran compared with warfarin. Of note, DOAC treatment was ... See full document

... trial involving patients with acute VTE who were initially given parenteral anticoagulation therapy for a median of 9 days. The investigators compared oral dabigatran, administered at a dose of 150 mg twice daily, ... See full document

... for venous thromboembolism prevention after THR or TKR was undertaken using bleeding rates relative to those caused by the same dose of enoxaparin for each ...perform direct comparisons of dabigatran ... See full document

... of venous thromboembolism ...antagonist oral anticoagulants (NOACs) into routine clinical practice, it is now possible for the initial acute management of patients with deep-vein thrombosis to ... See full document

... new oral anticoagulants to replace warfarin have also been ...sought. Oral vitamin K antagonists (war- farin) are used for long-term anticoagulation ...new oral anticoagulants was the ... See full document

... NOACs first gained approval for nonvalvular atrial fibril- lation, and since then approval has been sought for treatment of VTE and postoperative venous thromboprophylaxis. Not all NOACs have the indication for ... See full document

... cessation); venous or arterial thromboembolic (TE) event (with supportive imaging re- sults and/or blood work); length of hospital stay; and hospital discharge status (alive, ... See full document

... oral direct factor Xa inhibitor advanced to phase III clinical trials. It has favorable pharmacokinetic characteristics with a bioavailability of 60%–80%. Rivaroxaban achieves peak plasma levels in three ... See full document

... new anticoagulants currently under investigation are small molecules with a selective and direct anti-Xa or antithrombin action, allowing oral administration in fixed ...of venous ... See full document

... only oral anticoagulants available for stroke prevention in the setting of atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE) prophylaxis after orthopedic procedures, as well as for ... See full document

... Investigators: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized ...acute venous ... See full document

... Ximelagatran appears to be an effective agent for both prevention and treatment of VTE. At doses studied, when used alone as an oral agent it has superior efficacy to warfarin for preventing VTE post TKR, but ... See full document